Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 Combined With Immunotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT07254585Phase 2Recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CPO301 in head and neck squamous cell carcinoma (HNSCC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Dec 2025; status: recruiting.
02
Drugs
CPO301
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07254585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07254585.